Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT2O84V)

• DTT Name: Thromboxane A2 receptor (TBXA2R) DTT Info
• Gene Name: TBXA2R

Molecule-Related Drug & Molecule List

3 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alprostadil	DMWH7NQ	Aorta coarctation		Approved	[1]
Ridogrel	DMWH9CN	Acute myocardial infarction	BA41	Approved	[2]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[3]

11 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ramatroban	DMB8UQ3	Perennial allergic rhinitis	CA08.03	Phase 2/3	[4]
FK-070	DMJSD5W	Angina pectoris	BA40	Phase 2	[5]
Ifetroban	DMEV39E	Aspirin-induced asthma	CA23.20	Phase 2	[6]
Ifetroban sodium	DMZP84Y	Thrombosis	DB61-GB90	Phase 2	[7]
KP-496	DMCO8UZ	Asthma	CA23	Phase 2	[8]
TAK-128	DMHPEFS	Diabetic neuropathy	8C0Z	Phase 2	[9]
BIBV 308	DMUBMN5	Peripheral vascular disease	BD4Z	Phase 1	[7]
DT-TX-30	DM1FX09	Angina pectoris	BA40	Phase 1	[10]
G-619	DM3H6YC	Thrombosis	DB61-GB90	Phase 1	[11]
YM-57158	DMS31YW	Allergic rhinitis	CA08.0	Phase 1	[12]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[13]

18 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Domitroban	DM3OUWC	Thrombosis	DB61-GB90	Discontinued in Preregistration	[14]
DALTROBAN	DMNQIKV	N. A.	N. A.	Discontinued in Phase 3	[15]
Seratrodast	DMPNTDL	Allergic asthma	CA23.0	Discontinued in Phase 3	[16]
Terutroban sodium	DMYF1DN	Thrombosis	DB61-GB90	Discontinued in Phase 3	[17]
ICI-192605	DMY8X6Q	Thrombosis	DB61-GB90	Discontinued in Phase 2	[18]
Linotroban	DM32JL5	Thrombosis	DB61-GB90	Discontinued in Phase 2	[19]
SQ-30741	DMTC4VY	Thrombosis	DB61-GB90	Discontinued in Phase 2	[20]
Z-335	DM2438J	Thrombosis	DB61-GB90	Discontinued in Phase 2	[21]
CGS-22652	DMF05DL	Angina pectoris	BA40	Discontinued in Phase 1	[22]
KT2-962	DMBH5G3	Thrombosis	DB61-GB90	Discontinued in Phase 1	[23]
KW-3635	DMG068H	Thrombosis	DB61-GB90	Discontinued in Phase 1	[24]
L-657925	DMOTY3G	N. A.	N. A.	Terminated	[25]
ON-579	DMTS6HB	Asthma	CA23	Terminated	[26]
SQ-33961	DMZBQ4I	Thrombosis	DB61-GB90	Terminated	[27]
Sulotroban	DM4SVIR	Asthma	CA23	Terminated	[28]
UP-116-77	DMEIR7F	Thrombosis	DB61-GB90	Terminated	[29]
Vapiprost	DMJLV03	Cardiovascular disease	BA00-BE2Z	Terminated	[30]
ZT-386	DM193WR	Asthma	CA23	Terminated	[31]

27 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
10,10-difluoro TXA2	DML745Y	Discovery agent	N.A.	Investigative	[32]
AGN 191976	DMTPV4Y	Discovery agent	N.A.	Investigative	[33]
AGN192093	DMISJXB	Discovery agent	N.A.	Investigative	[33]
AH23848	DM4S1Y6	Discovery agent	N.A.	Investigative	[13]
BM-573	DMD2H7L	Discovery agent	N.A.	Investigative	[34]
butaprost (free acid form)	DM5MZHP	Discovery agent	N.A.	Investigative	[13]
carbacyclin	DMMBQYE	Discovery agent	N.A.	Investigative	[13]
carbocyclic thromboxane A2	DMGKSVF	Discovery agent	N.A.	Investigative	[35]
cloprostenol	DMH01JV	Discovery agent	N.A.	Investigative	[13]
EP 171	DM7YION	Discovery agent	N.A.	Investigative	[36]
fluprostenol	DM9Q2PG	Discovery agent	N.A.	Investigative	[13]
I-BOP	DMJAPML	Discovery agent	N.A.	Investigative	[37]
I-SAP	DMJ2FQA	Discovery agent	N.A.	Investigative	[38]
M&B 28767	DMJQG82	Discovery agent	N.A.	Investigative	[13]
ONO-3708	DM84IW9	Discovery agent	N.A.	Investigative	[39]
ONO-8809	DM5BMA9	Thrombosis	DB61-GB90	Investigative	[40]
PGH2	DMZFVGC	Discovery agent	N.A.	Investigative	[35]
S 18204	DM2FC5V	Discovery agent	N.A.	Investigative	[41]
SQ 26655	DMRP42B	Discovery agent	N.A.	Investigative	[42]
SQ-29548	DM9G3UD	Discovery agent	N.A.	Investigative	[13]
STA2	DMIYJ2M	Discovery agent	N.A.	Investigative	[37]
U-44069	DM0DMNS	Discovery agent	N.A.	Investigative	[43]
U46619	DM13FX4	Discovery agent	N.A.	Investigative	[13]
[125I]BOP	DMV6I7H	Discovery agent	N.A.	Investigative	[44]
[125I]PTA-OH	DMROKJP	Discovery agent	N.A.	Investigative	[45]
[125I]SAP	DM1DXHG	Discovery agent	N.A.	Investigative	[38]
[125I]SQ-29548	DM0GKMA	Discovery agent	N.A.	Investigative	[46]

References

• [1] Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6.
• [2] Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42.
• [3] Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
• [4] Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7.
• [5] Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
• [6] Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev. 2001 Summer;19(2):97-115.
• [7] AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.
• [8] Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
• [9] ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
• [10] DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. Basic Res Cardiol. 1997 Jun;92(3):181-90.
• [11] G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
• [12] In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
• [13] The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
• [14] The effect of a novel thromboxane A2 (TXA2) receptor antagonist (S-1452) on the antigen-induced bronchoconstriction and airway hyperresponsiveness in guinea pigs. Prostaglandins Leukot Essent Fatty Acids. 1993 May;48(5):343-9.
• [15] Synthesis and thromboxane A2/prostaglandin H2 receptor antagonistic activity of phenol derivatives. J Med Chem. 1992 Jun 12;35(12):2202-9.
• [16] Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. Am J Respir Med. 2002;1(1):11-7.
• [17] Terutroban and endothelial TP receptors in atherogenesis. Med Sci (Paris). 2006 Apr;22(4):437-43.
• [18] The effects of thromboxane receptor blockade on platelet aggregation and digital skin blood flow in patients with secondary Raynaud's syndrome. Rheumatol Int. 1991;11(4-5):163-8.
• [19] Effects of the novel thromboxane (TXA2) receptor antagonist linotroban on inulin and para-aminohippuric acid clearances in the conscious male and female rat. Arzneimittelforschung. 1997 Sep;47(9):1026-30.
• [20] Influence of SQ 30741 on thromboxane receptor-mediated responses in the feline pulmonary vascular bed. J Appl Physiol (1985). 1991 Nov;71(5):2012-8.
• [21] Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. J Clin Pharmacol. 2002 Jul;42(7):782-90.
• [22] Blood pressure effects of thromboxane A2 blockade in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1993 Nov;20(11):679-87.
• [23] Azulene derivatives as TXA2/PGH2 receptor antagonists--II. Synthesis and biological activity of 6-mono- and 6-dihydroxylated-isopropylazulenes. Bioorg Med Chem. 1996 Apr;4(4):575-91.
• [24] Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs. Jpn J Pharmacol. 1994 Jun;65(2):93-8.
• [25] Novel synthesis and biochemical properties of an [125I]-labeled photoaffinity probe for thromboxane A2/prostaglandin H2 receptors. J Med Chem. 1991 Apr;34(4):1511-4.
• [26] The effect of a TXA2 receptor antagonist ON-579 on experimental allergic reactions. Prostaglandins Leukot Essent Fatty Acids. 1995 Aug;53(2):123-33.
• [27] Conformationally-restricted analogs of TXA2 antagonist SQ 33,961: Receptor binding conformation of the carboxyl sidechain. Bioorganic & Medicinal Chemistry Letters Volume 1, Issue 9, 1991, Pages 465-470.
• [28] The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation. Prostaglandins. 1988 Dec;36(6):751-60.
• [29] Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4,5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists. J Med Chem. 1993 Apr 30;36(9):1175-87.
• [30] Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.. Br J Pharmacol. 1992 July; 106(3): 533-538.
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004057)
• [32] Difluorothromboxane A2 and stereoisomers: stable derivatives of thromboxane A2 with differential effects on platelets and blood vessels. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5600-4.
• [33] Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha. Br J Pharmacol. 1996 Mar;117(6):1171-80.
• [34] Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta iso... J Med Chem. 2006 Jun 15;49(12):3701-9.
• [35] Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat platelets. Jpn J Pharmacol. 1992 Jul;59(3):357-64.
• [36] EP 171: a high affinity thromboxane A2-mimetic, the actions of which are slowly reversed by receptor blockade. Br J Pharmacol. 1989 Apr;96(4):875-87.
• [37] Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
• [38] 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors. J Pharmacol Exp Ther. 1992 Aug;262(2):632-7.
• [39] Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548). Thromb Res. 1986 Feb 15;41(4):471-81.
• [40] Anti-thrombotic effect of ONO-8809, a novel TXA2/PG endoperoxide receptor antagonist. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:599-602.
• [41] Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost. 2004 Mar;2(3):492-8.
• [42] Synthesis and in vitro pharmacology of 7-oxabicyclo[2.2.1]heptane analogues of thromboxane A2/PGH2. J Med Chem. 1985 Nov;28(11):1580-90.
• [43] cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
• [44] Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist. J Pharmacol Exp Ther. 1989 Nov;251(2):557-62.
• [45] Binding of thromboxane A2/prostaglandin H2 agonists to human platelets. Br J Pharmacol. 1987 May;91(1):223-7.
• [46] Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets. J Pharmacol Exp Ther. 1988 Jun;245(3):786-92.